Stein Larssen-Saeboe

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Large-Scale Production of Unmodified mRNA for Reprogramming Human Dendritic Cells and T Cells.

Large-Scale Production of Unmodified mRNA for Reprogramming Human Dendritic Cells and T Cells.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: August 28, 2025

Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.

Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: August 28, 2025

Production of mRNA-Loaded Dendritic Cell Cancer Vaccines.

Production of mRNA-Loaded Dendritic Cell Cancer Vaccines.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: August 28, 2025

Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens.

Exploring the Impact of mRNA Modifications on Translation Efficiency and Immune Tolerance to Self-Antigens.

Journal: Vaccines

Published: May 06, 2024

Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.

Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 21, 2024

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).

Journal: Frontiers in oncology

Published: August 29, 2022

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.

Journal: The Prostate

Published: July 12, 2021

Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference.

Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: February 02, 2020

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.

Journal: Case reports in medicine

Published: March 11, 2016

Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.

Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 17, 2014

Light-controlled modulation of gene expression using polyamidoamine formulations.

Light-controlled modulation of gene expression using polyamidoamine formulations.

Journal: Nucleic acid therapeutics

Published: March 28, 2013

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.

Journal: Cancer immunology, immunotherapy : CII

Published: February 15, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026